Browsing Tag
Hyperphosphatemia
1 post
Unicycive (NASDAQ: UNCY) hit by FDA manufacturing concerns ahead of oxylanthanum carbonate decision
Unicycive’s NDA for oxylanthanum carbonate faces FDA manufacturing concerns. Key decision expected June 28. Read the stock outlook and next steps.